Dengue Fever, the second largest tropical disease, now has a new enemy. Thanks to collaborators at the Centers for Disease Control and Prevention, a new vaccination is on the horizon and shows promise in pre-clinical animal models. According to the press release, the Centers for Disease Control and Prevention will be partnering with the Pediatric Dengue Vaccine Initiative (PDVI) in the fight against Dengue Fever.
Dengue Fever is characterized by a sudden fever, sever headache, muscle pain, joint pain and rashes. Dengue Fever is a hemorrhagic fever, which means the body may begin to bleed while infected with the virus. Bleeding may manifest as spontaneous bruising, vomiting blood or bloody diarrhea. While Dengue Fever is spread similarly to Malaria, Dengue Fever continues to be prominent even in urban areas with high populations. Due to the various levels of severity Dengue Fever represents in the body, milder cases are often misdiagnosed a influenza or any of a multitude of viral infections. More than 50 million people contract the Dengue Fever Virus each year with a potential infection of more than 3.5 billion, the press release reported.
In recent years, Dengue Fever has begun to spread to more popular and populous areas such as Singapore and Australia. According to the press release, travelers to and worker in endemic regions are infected with the virus as well.
Treatment of Dengue Fever includes increased fluid intake to prevent dehydration and possible platelet transfusion in rare cases where platelet levels drop below 20,000.
The Centers for Disease Control and Prevention, according to the press release, plans to make the immunization widespread and affordable for the large populations in underdeveloped nations.
The company at the heart of the Pediatric Dengue Vaccine Initiative, Inviragen, was co-founded by Dr. Jorge Osoris and Dr. Dan Stinchcomb. The company has helped to produce many vaccines in hopes of preventing the more than 15 million deaths each year attributed to infectious diseases.
Inviragen, with the help of the International Vaccine Institute, “have formed an international consortium to move Inviragen’s Dengue Vaccine into human clinical trials. . .”, the press release reported Dr. Dan Stinchcomb stated.
Inviragen is also in the process of creating a vaccine for the West Nile disease and a combination vaccine for the prevention of the plague and smallpox.
With the collaboration of these immunization creators, the Dengue Fever vaccination may soon begin clinical trials and thereafter be available for mass production.
Inviragen; The Pediatric Dengue Initiative and Inviragen Partner to Prevent Dengue Fever; PR Newswire
Dengue Fever; Dengue Fever; Wikipedia